Key result
Integrated management of T2D and hypertension targets shared pathways to reduce cardiorenal risk.
Why the study?
Type 2 diabetes mellitus and hypertension frequently coexist through shared pathophysiological mechanisms, substantially increasing the risk of cardiovascular disease, stroke, and kidney complications.
Answers are grounded in this paper and cite their sources.
This narrative review highlights the shared pathophysiological mechanisms of coexisting type 2 diabetes mellitus and hypertension and emphasizes the need for integrated, individualized cardiometabolic and renal risk-directed management.
Type 2 diabetes mellitus (T2DM) and hypertension are common chronic disorders that frequently coexist and substantially increase the risk of cardiovascular disease, stroke, and kidney complications. Their association is supported by shared mechanisms, including insulin resistance, chronic low-grade inflammation, oxidative stress, endothelial dysfunction, and activation of the renin–angiotensin–aldosterone system (RAAS). Persistent hyperglycaemia contributes to vascular injury, while elevated blood pressure can accelerate renal and cardiovascular damage and is commonly associated with metabolic dysfunction. This narrative review summarizes the epidemiology and shared risk factors of T2DM and hypertension, explains their interrelated pathophysiology, and discusses symptoms, diagnosis, lifestyle measures, and pharmacological management. Antidiabetic treatment may include metformin, sodium–glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists, selected according to individual clinical characteristics. Antihypertensive treatment may include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, and thiazide-like diuretics. Calcium channel blocker mechanisms and important adverse effects are also reviewed. Integrated care, early detection, individualized treatment, and regular monitoring of blood glucose, blood pressure, kidney function, and cardiovascular risk are essential to reduce complications.
No takes yet. Share an insight, caveat, or question.
Mantriwar et al. (2026) conducted a review in Co-existing Type 2 Diabetes Mellitus and Hypertension. Integrated lifestyle and pharmacological management (antidiabetic and antihypertensive agents) was evaluated. Type 2 diabetes mellitus and hypertension share pathophysiological pathways like insulin resistance and RAAS activation, requiring integrated management to reduce cardiovascular and renal risk.
Synapse has enriched 10 related papers. Consider them for comparative context: